Neurogene Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NGNE | NGEN | RGNX | ALEC | VYGR | TSHA | |
|---|---|---|---|---|---|---|
| Market cap | 489.08M | 186.01M | 512.92M | 232.25M | 139.87M | 1.35B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -4.3 | -5.1 | -2.6 | -2.8 | -1.8 | -9.0 |
| Price/book | 1.8 | 14.9 | 5.9 | -23.4 | 0.9 | 5.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −16.51% | −48.73% | −28.84% | −30.43% | −49.90% | −11.09% |
| Today | −7.42% | 0.00% | −3.72% | 0.00% | −7.35% | −7.80% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All NGNE news ›Stifel Nicolaus Sticks to Their Buy Rating for Neurogene (NGNE)
Stifel Nicolaus analyst Paul Matteis reiterated a Buy rating on Neurogene today and set a price target of $46.00. Matteis covers the Healthcare sector, focusing on stocks such as Definium Therapeutics, BioMarin Pharmaceutical, and ACADIA…
Neurogene (NGNE) Receives a Buy from LifeSci Capital
In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Neurogene, with a price target of $65.00. Dolezal covers the Healthcare sector, focusing on stocks such as Neurogene, Oculis Holding, and Ibio.…
Neurogene Completes Dosing in Embolden Rett Trial
An update from Neurogene ( (NGNE) ) is now available. The most recent analyst rating on (NGNE) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Neurogene stock, see the NGNE Stock Forecast page.…
Neurogene bolsters cash runway with equity offering
An update from Neurogene ( (NGNE) ) is now available. The most recent analyst rating on (NGNE) stock is a Buy with a $69.00 price target. To see the full list of analyst forecasts on Neurogene stock, see the NGNE Stock Forecast page.…
Neurogene Stockholders Vote on Directors and Executive Pay
Neurogene ( (NGNE) ) has provided an update. On June 3, 2026, Neurogene Inc. held its 2026 Annual Meeting of Stockholders, where a quorum of approximately 72.92% of eligible voting power was present in person or by proxy. Stockholders…
Neurogene Advances Rett Gene Therapy Program and Extends Cash Runway to 2029
Neurogene ( (NGNE) ) just unveiled an announcement. The most recent analyst rating on (NGNE) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Neurogene stock, see the NGNE Stock Forecast page. Spark’s…
Analysts’ Top Healthcare Picks: ProQR (PRQR), Neurogene (NGNE)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ProQR (PRQR) and Neurogene (NGNE) with bullish sentiments. In a report released today, Ananda Ghosh from H.C. Wainwright maintained a Buy rating…
Analysts’ Top Healthcare Picks: Argenx Se (ARGX), Neurogene (NGNE)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Argenx Se (ARGX) and Neurogene (NGNE) with bullish sentiments. In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a…
Neurogene Inc (NGNE-Q) Stock Price and News
The Globe and Mail Instrument NameNeurogene IncInstrument Symbol(NGNE-Q)
Analysts Are Bullish on Top Healthcare Stocks: Acurx Pharmaceuticals (ACXP), Neurogene (NGNE)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Acurx Pharmaceuticals (ACXP) and Neurogene (NGNE) with bullish sentiments. Alliance Global Partners analyst James Molloy reiterated a Buy rating…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
theglobeandmail.com12
-
stocktitan.net6
-
themarketsdaily.com1
-
tradingview.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 20 articles, not a forecast.